{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T16:25:46Z","timestamp":1788452746810,"version":"build-2803163510"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatologie"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s00105-026-05754-7","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T12:24:07Z","timestamp":1785846247000},"page":"593-601","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Aktuelle und zuk\u00fcnftige Therapien von bradykininvermittelten Angio\u00f6demen","Current and future therapies for bradykinin-mediated angioedema"],"prefix":"10.1007","volume":"77","author":[{"given":"Maria","family":"Fasshauer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Dominas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"key":"5754_CR1","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1111\/all.15214","volume":"77","author":"M Maurer","year":"2022","unstructured":"Maurer\u00a0M, Magerl\u00a0M, Betschel\u00a0S, Aberer\u00a0W, Ansotegui\u00a0IJ, Ayg\u00f6ren-P\u00fcrs\u00fcn\u00a0E, Banerji\u00a0A, Bara\u00a0NA, Boccon-Gibod\u00a0I, Bork\u00a0K, Bouillet\u00a0L, Boysen\u00a0HB, Brodszki\u00a0N, Busse\u00a0PJ, Bygum\u00a0A, Caballero\u00a0T, Cancian\u00a0M, Castaldo\u00a0A, Cohn\u00a0DM, Csuka\u00a0D et\u00a0al (2022) The international WAO\/EAACI guideline for the management of hereditary angioedema-The 2021 revision and update. Allergy 77:1961\u20131990. https:\/\/doi.org\/10.1111\/all.15214","journal-title":"Allergy"},{"key":"5754_CR2","doi-asserted-by":"publisher","DOI":"10.1111\/all.70207","author":"H Farkas","year":"2026","unstructured":"Farkas\u00a0H, Martinez-Saguer\u00a0I, Bork\u00a0K et\u00a0al (2026) International Guideline on the Diagnosis and Management of Pediatric Patients With Hereditary Angioedema. Allergy. https:\/\/doi.org\/10.1111\/all.70207","journal-title":"Allergy"},{"key":"5754_CR3","unstructured":"Fachinformation Berinert 500\/1500 https:\/\/www.berinert.de\/documents\/64158\/69464\/FI_Berinert_April_2016.pdf\/a5ed7d04-0c28-4f5a-994d-896a1e8031cd"},{"key":"5754_CR4","unstructured":"Fachinformation Cinryze 500 https:\/\/www.takeda-produkte.de\/system\/files\/produkt-info\/fachinformation-cinryzer-500-ie-pulver-und-losungsmittel-zur-herstellung-einer-injektionslosung.pdf"},{"key":"5754_CR5","unstructured":"EMA Produktinformation Ruconest https:\/\/www.ema.europa.eu\/de\/documents\/product-information\/ruconest-epar-product-information_de.pdf"},{"key":"5754_CR6","unstructured":"Fachinformation Firazyr https:\/\/www.takeda-produkte.de\/system\/files\/produkt-info\/fachinformation-firazyrr-30-mg-injektionslosung-fertigspritze.pdf"},{"key":"5754_CR7","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/S0140-6736(22)02406-0","volume":"401","author":"E Ayg\u00f6ren-P\u00fcrs\u00fcn","year":"2023","unstructured":"Ayg\u00f6ren-P\u00fcrs\u00fcn\u00a0E, Zanichelli\u00a0A, Cohn\u00a0DM, Cancian\u00a0M, Hakl\u00a0R, Kinaciyan\u00a0T, Magerl\u00a0M, Martinez-Saguer\u00a0I, Stobiecki\u00a0M, Farkas\u00a0H, Kiani-Alikhan\u00a0S, Grivcheva-Panovska\u00a0V, Bernstein\u00a0JA, Li\u00a0HH, Longhurst\u00a0HJ, Audhya\u00a0PK, Smith\u00a0MD, Yea\u00a0CM, Maetzel\u00a0A, Lee\u00a0DK et\u00a0al (2023) An investigational oral plasma kallikrein inhibitor for on-demand treatment of hereditary angioedema: a two-part, randomised, double-blind, placebo-controlled, crossover phase 2 trial. Lancet 401:458\u2013469. https:\/\/doi.org\/10.1016\/S0140-6736(22)02406-0","journal-title":"Lancet"},{"key":"5754_CR8","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/NEJMoa2314192","volume":"391","author":"MA Riedl","year":"2024","unstructured":"Riedl\u00a0MA, Farkas\u00a0H, Ayg\u00f6ren-P\u00fcrs\u00fcn\u00a0E, Psarros\u00a0F, Soteres\u00a0DF, Staevska\u00a0M, Cancian\u00a0M, Hagin\u00a0D, Honda\u00a0D, Melamed\u00a0I, Savic\u00a0S, Stobiecki\u00a0M, Busse\u00a0PJ, Dias de Castro\u00a0E, Agmon-Levin\u00a0N, Gower\u00a0R, Kessel\u00a0A, Kurowski\u00a0M, Lleonart\u00a0R, Grivcheva Panovska\u00a0V, KONFIDENT Investigators et\u00a0al (2024) Oral Sebetralstat for On-Demand Treatment of Hereditary Angioedema Attacks. N Engl J Med 391:32\u201343. https:\/\/doi.org\/10.1056\/NEJMoa2314192","journal-title":"N Engl J Med"},{"key":"5754_CR9","unstructured":"EMA Produkt Information Ekterly https:\/\/www.ema.europa.eu\/de\/documents\/product-information\/ekterly-epar-product-information_de.pdf"},{"issue":"10375","key":"5754_CR10","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/s0140-6736(22)02406-0","volume":"401","author":"E Ayg\u00f6ren-P\u00fcrs\u00fcn","year":"2023","unstructured":"Ayg\u00f6ren-P\u00fcrs\u00fcn\u00a0E, Zanichelli\u00a0A, Cohn\u00a0DM et\u00a0al (2023) An Investigational Oral Plasma Kallikrein Inhibitor for On-Demand Treatment of Hereditary Angioedema: A Two-Part, Randomised, Double-Blind, Placebo-Controlled, Crossover Phase 2 Trial. Lancet 401(10375):458\u2013469. https:\/\/doi.org\/10.1016\/s0140-6736(22)02406-0","journal-title":"Lancet"},{"key":"5754_CR11","doi-asserted-by":"crossref","unstructured":"Adatia A, Ayg\u00f6ren-P\u00fcrs\u00fcn E, Cancian M et\u00a0al. SEBETRALSTAT FOR ON-DEMAND TREATMENT OF HEREDITARY ANGIOEDEMA IN PEDIATRIC (2-11Y) PATIENTS: INTERIM RESULTS FROM KONFIDENT-KID Annals of Allergy, Asthma & Immunology, 135S2 https:\/\/www.annallergy.org\/action\/showPdf?pii=S1081-1206%2825%2901269-4","DOI":"10.1016\/j.anai.2025.10.017"},{"key":"5754_CR12","unstructured":"https:\/\/ir.kalvista.com\/news-releases\/news-release-details\/kalvista-pharmaceuticals-announces-positive-interim-phase-3-data\/"},{"key":"5754_CR13","unstructured":"Fachinformation Berinert 2000\/3000 https:\/\/www.berinert.de\/documents\/64158\/69464\/FI-Berinert-2000-3000.pdf\/36700bdf-91ee-4b0a-80f2-a26ecaf65a88"},{"key":"5754_CR14","unstructured":"Fachinformation Orladeyo https:\/\/www.fachinfo.de\/fi\/pdf\/023436\/orladeyo-150-mg-hartkapseln"},{"key":"5754_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.10.015","author":"B Zuraw","year":"2020","unstructured":"Zuraw\u00a0B, Lumry\u00a0W, Johnston\u00a0D, Ayg\u00f6ren-P\u00fcrs\u00fcn\u00a0E, Banerji\u00a0A (2020) Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trial. J\u00a0Allergy Clin Immunol. https:\/\/doi.org\/10.1016\/j.jaci.2020.10.015","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"3","key":"5754_CR16","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.jaip.2023.12.019","volume":"12","author":"S Kiani-Alikhan","year":"2024","unstructured":"Kiani-Alikhan\u00a0S, Gower\u00a0R, Craig\u00a0T, Wedner\u00a0HJ, Kinaciyan\u00a0T, Ayg\u00f6ren-P\u00fcrs\u00fcn\u00a0E, Banerji\u00a0A, Bernstein\u00a0JA, Anderson\u00a0J, Collis\u00a0P, Johnston\u00a0DT, Desai\u00a0B, Tomita\u00a0D, Gagnon\u00a0R, Tachdjian\u00a0R, Soteres\u00a0DF, Farkas\u00a0H, Caballero\u00a0T, McNeil\u00a0D, Jacobs\u00a0J, Lumry\u00a0WR, APeX\u20112 investigators (2024) Once-Daily Oral Berotralstat for Long-Term Prophylaxis of Hereditary Angioedema: The Open-Label Extension of the APeX\u20112 Randomized Trial. J\u00a0Allergy Clin Immunol Pract 12(3):733\u2013743.e10. https:\/\/doi.org\/10.1016\/j.jaip.2023.12.019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"5754_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/clt2.12035","volume":"11","author":"H Farkas","year":"2021","unstructured":"Farkas\u00a0H, Stobiecki\u00a0M, Peter\u00a0J, Kinaciyan\u00a0T, Maurer\u00a0M, Ayg\u00f6ren-P\u00fcrs\u00fcn\u00a0E, Kiani-Alikhan\u00a0S, Wu\u00a0A, Reshef\u00a0A, Bygum\u00a0A, Fain\u00a0O, Hagin\u00a0D, Huissoon\u00a0A, Jese\u0148\u00e1k\u00a0M, Lindsay\u00a0K, Panovska\u00a0VG, Steiner\u00a0UC, Zubrinich\u00a0C, Best\u00a0JM, Cornpropst\u00a0M, Dix\u00a0D, Dobo\u00a0SM, Iocca\u00a0HA, Desai\u00a0B, Murray\u00a0SC, Nagy\u00a0E, Sheridan\u00a0WP (2021) Long-term safety and effectiveness of berotralstat for hereditary angioedema: The open-label APeX\u2011S study. Clin Transl Allergy 11:e12035. https:\/\/doi.org\/10.1002\/clt2.12035","journal-title":"Clin Transl Allergy"},{"issue":"6","key":"5754_CR18","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.anai.2025.07.012","volume":"135","author":"J Bernatoniene","year":"2025","unstructured":"Bernatoniene\u00a0J, Bourgoin-Heck\u00a0M, Cancian\u00a0M, Yang\u00a0W, Hagin\u00a0D, Pagnier\u00a0A, Stobiecki\u00a0M, Kinaciyan\u00a0T, Phillips-Angles\u00a0E, Gayet\u00a0S, Bara\u00a0NA, Hunter\u00a0J, Mateescu\u00a0E, DeSpirito\u00a0M, Johnston\u00a0D, Long\u00a0D, Iocca\u00a0H, Petroni\u00a0D, Ayg\u00f6ren-P\u00fcrs\u00fcn\u00a0E (2025) Oral berotralstat for hereditary angioedema prophylaxis in patients aged 2 to \u3008\u202f12\u00a0years: APeX\u2011P interim results. Ann Allergy Asthma Immunol 135(6):681\u2013688.e3. https:\/\/doi.org\/10.1016\/j.anai.2025.07.012","journal-title":"Ann Allergy Asthma Immunol"},{"key":"5754_CR19","unstructured":"FDA Orladeyo https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/214094s005lbl.pdf"},{"issue":"20","key":"5754_CR20","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1001\/jama.2018.16773","volume":"320","author":"A Banerji","year":"2018","unstructured":"Banerji\u00a0A, Riedl\u00a0MA, Bernstein\u00a0JA, HELP Investigators et\u00a0al (2018) Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks. JAMA 320(20):2108\u20132121. https:\/\/doi.org\/10.1001\/jama.2018.16773","journal-title":"JAMA"},{"issue":"11","key":"5754_CR21","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1111\/all.14416","volume":"75","author":"MA Riedl","year":"2020","unstructured":"Riedl\u00a0MA, Maurer\u00a0M, Bernstein\u00a0JA, HELP Investigators et\u00a0al (2020) Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks. Allergy 75(11):2879\u20132887. https:\/\/doi.org\/10.1111\/all.14416","journal-title":"Allergy"},{"issue":"1","key":"5754_CR22","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.jaip.2023.09.009","volume":"12","author":"M Maurer","year":"2024","unstructured":"Maurer\u00a0M, Lumry\u00a0WR, Li\u00a0HH, Ayg\u00f6ren-P\u00fcrs\u00fcn\u00a0E, Busse\u00a0PJ, Jacobs\u00a0J, Nurse\u00a0C, Ahmed\u00a0MA, Watt\u00a0M, Yu\u00a0M, SPRING Investigators (2024) Lanadelumab in Patients 2 to Less Than 12 Years Old With Hereditary Angioedema: Results From the Phase 3 SPRING Study. J\u00a0Allergy Clin Immunol Pract 12(1):201\u2013211.e6. https:\/\/doi.org\/10.1016\/j.jaip.2023.09.009","journal-title":"J Allergy Clin Immunol Pract"},{"key":"5754_CR23","unstructured":"Fachinformation Takzhyro 150\/300\u202fmg https:\/\/www.takeda-produkte.de\/system\/files\/produkt-info\/fachinformation-takhzyro-150-mg300-mg-injektionslosung-einer-fertigspritze-takhzyror-300-mg.pdf"},{"issue":"10382","key":"5754_CR24","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/S0140-6736(23)00350-1","volume":"401","author":"TJ Craig","year":"2023","unstructured":"Craig\u00a0TJ, Reshef\u00a0A, Li\u00a0HH, Jacobs\u00a0JS, Bernstein\u00a0JA, Farkas\u00a0H, Yang\u00a0WH, Stroes\u00a0ESG, Ohsawa\u00a0I, Tachdjian\u00a0R, Manning\u00a0ME, Lumry\u00a0WR, Saguer\u00a0IM, Ayg\u00f6ren-P\u00fcrs\u00fcn\u00a0E, Ritchie\u00a0B, Sussman\u00a0GL, Anderson\u00a0J, Kawahata\u00a0K, Suzuki\u00a0Y, Staubach\u00a0P, Treudler\u00a0R, Feuersenger\u00a0H, Glassman\u00a0F, Jacobs\u00a0I, Magerl\u00a0M (2023) Efficacy and safety of garadacimab, a\u00a0factor\u00a0XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a\u00a0global, multicentre, randomised, double-blind, placebo-controlled, phase\u00a03\u00a0trial. Lancet 401(10382):1079\u20131090. https:\/\/doi.org\/10.1016\/S0140-6736(23)00350-1","journal-title":"Lancet"},{"key":"5754_CR25","unstructured":"Fachinformation Andembry https:\/\/www.cslbehring.de\/-\/media\/cslb-germany\/documents\/produktliste-fachinformationen\/de_fi_andembry_febr_25.pdf"},{"issue":"1","key":"5754_CR26","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1056\/NEJMoa2402478","volume":"391","author":"MA Riedl","year":"2024","unstructured":"Riedl\u00a0MA, Tachdjian\u00a0R, Lumry\u00a0WR, Craig\u00a0T, Karakaya\u00a0G, Gelincik\u00a0A, Stobiecki\u00a0M, Jacobs\u00a0JS, Gokmen\u00a0NM, Reshef\u00a0A, Gompels\u00a0MM, Manning\u00a0ME, Bordone\u00a0L, Newman\u00a0KB, Treadwell\u00a0S, Wang\u00a0S, Yarlas\u00a0A, Cohn\u00a0DM, OASIS-HAE Team (2024) Efficacy and Safety of Donidalorsen for Hereditary Angioedema. N Engl J Med 391(1):21\u201331. https:\/\/doi.org\/10.1056\/NEJMoa2402478","journal-title":"N Engl J Med"},{"issue":"8","key":"5754_CR27","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1111\/all.16563","volume":"80","author":"MA Riedl","year":"2025","unstructured":"Riedl\u00a0MA, Yarlas\u00a0A, Bordone\u00a0L, Treadwell\u00a0S, Wang\u00a0S, Newman\u00a0KB, Cohn\u00a0DM (2025) Patient-Reported Outcomes in the Phase III OASIS-HAE Study of Donidalorsen for Hereditary Angioedema. Allergy 80(8):2361\u20132368. https:\/\/doi.org\/10.1111\/all.16563","journal-title":"Allergy"},{"key":"5754_CR28","unstructured":"Fachinformation Dawnzera https:\/\/www.fachinfo.de\/fi\/pdf\/025669\/dawnzera-r-80-mg-injektionsloesung-im-fertigpen"},{"issue":"11","key":"5754_CR29","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1056\/NEJMoa2109329","volume":"386","author":"LM Fijen","year":"2022","unstructured":"Fijen\u00a0LM, Riedl\u00a0MA, Bordone\u00a0L, Bernstein\u00a0JA, Raasch\u00a0J, Tachdjian\u00a0R, Craig\u00a0T, Lumry\u00a0WR, Manning\u00a0ME, Alexander\u00a0VJ, Newman\u00a0KB, Revenko\u00a0A, Baker\u00a0BF, Nanavati\u00a0C, MacLeod\u00a0AR, Schneider\u00a0E, Cohn\u00a0DM (2022) Inhibition of Prekallikrein for Hereditary Angioedema. N Engl J Med 386(11):1026\u20131033. https:\/\/doi.org\/10.1056\/NEJMoa2109329","journal-title":"N Engl J Med"},{"issue":"4","key":"5754_CR30","doi-asserted-by":"publisher","first-page":"e215","DOI":"10.1016\/S2352-3026(26)00004-9","volume":"13","author":"E Ayg\u00f6ren-P\u00fcrs\u00fcn","year":"2026","unstructured":"Ayg\u00f6ren-P\u00fcrs\u00fcn\u00a0E, Stobiecki\u00a0M, Valerieva\u00a0A, Cancian\u00a0M, Gompels\u00a0M, Grigoriadou\u00a0S, Kiani-Alikhan\u00a0S, Kinaciyan\u00a0T, Yang\u00a0WH, Anderson\u00a0J, Arcoleo\u00a0F, Chapdelaine\u00a0H, Conlon\u00a0N, Eren\u00a0E, Guarino\u00a0MD, Gurugama\u00a0P, Magerl\u00a0M, Manning\u00a0ME, Tarzi\u00a0MD, Wedner\u00a0HJ, Zanichelli\u00a0A, Crabb\u00e9\u00a0R, Mulders\u00a0S, Levy\u00a0J, Zhu\u00a0L, Knolle\u00a0J, Lesage\u00a0A, Lu\u00a0P, Riedl\u00a0MA (2026) Oral deucrictibant for prophylaxis of hereditary angioedema attacks (CHAPTER-1): primary analysis of a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Haematol 13(4):e215\u2013e226. https:\/\/doi.org\/10.1016\/S2352-3026(26)00004-9","journal-title":"Lancet Haematol"},{"issue":"4","key":"5754_CR31","doi-asserted-by":"publisher","first-page":"e200","DOI":"10.1016\/S2352-3026(25)00341-2","volume":"13","author":"M Maurer","year":"2026","unstructured":"Maurer\u00a0M, Stobiecki\u00a0M, Valerieva\u00a0A, Hakl\u00a0R, Staevska\u00a0MT, Bouillet\u00a0L, Du-Thanh\u00a0A, Kessel\u00a0A, Kiani-Alikhan\u00a0S, Magerl\u00a0M, Reshef\u00a0A, Baeza\u00a0ML, Fain\u00a0O, Farkas\u00a0H, Greve\u00a0J, Guilarte\u00a0M, Jacobs\u00a0JS, Li\u00a0HH, Lleonart\u00a0R, Manning\u00a0ME, Sussman\u00a0GL, Anderson\u00a0J, Chapdelaine\u00a0H, Cohn\u00a0DM, Hagin\u00a0D, Kr\u00e1l\u00ed\u010dkov\u00e1\u00a0P, Ritchie\u00a0B, Spadaro\u00a0G, Staubach\u00a0P, Tarzi\u00a0MD, Yang\u00a0WH, Jouvin\u00a0MH, Crabb\u00e9\u00a0R, van Leeuwen\u00a0S, Chen\u00a0H, Zhu\u00a0L, Knolle\u00a0J, Lesage\u00a0A, Lu\u00a0P, Riedl\u00a0MA, Ayg\u00f6ren-P\u00fcrs\u00fcn\u00a0E (2026) Oral deucrictibant for on-demand treatment of hereditary angioedema attacks (RAPIDe-1): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Haematol 13(4):e200\u2013e214. https:\/\/doi.org\/10.1016\/S2352-3026(25)00341-2","journal-title":"Lancet Haematol"},{"issue":"5","key":"5754_CR32","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/j.jaci.2026.02.034","volume":"157","author":"A Banerji","year":"2026","unstructured":"Banerji\u00a0A, Craig\u00a0T, Sitz\u00a0K et\u00a0al (2026) Open-Label Phase 1b\/2 Trial of Navenibart, a Long-Acting Plasma Kallikrein Inhibitor for Hereditary Angioedema. J\u00a0Allergy Clin Immunol 157(5):1127\u20131135.e6. https:\/\/doi.org\/10.1016\/j.jaci.2026.02.034","journal-title":"The Journal of Allergy and Clinical Immunology"},{"key":"5754_CR33","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2026.2664733","author":"H Farkas","year":"2026","unstructured":"Farkas\u00a0H, Voloncs-Mindszenthy\u00a0L, Horv\u00e1th\u00a0HR (2026) Monoclonal Antibodies in the Management of Hereditary Angioedema. Expert Opin Biol Ther. https:\/\/doi.org\/10.1080\/14712598.2026.2664733","journal-title":"Expert Opinion on Biological Therapy"},{"issue":"1","key":"5754_CR34","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.anai.2025.03.016","volume":"135","author":"W Lumry","year":"2025","unstructured":"Lumry\u00a0W, Gunsior\u00a0M, Cohen\u00a0T et\u00a0al (2025) Safety and Pharmacokinetics of Long-Acting Plasma Kallikrein Inhibitor Navenibart (STAR-0215) in Healthy Adults. Ann Allergy Asthma Immunol 135(1):103\u2013111.e2. https:\/\/doi.org\/10.1016\/j.anai.2025.03.016","journal-title":"Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology"},{"key":"5754_CR35","unstructured":"ADARx Pharmaceuticals to Present Onvuzosiran (ADX-324) Phase 1\/2 Clinical Data Supporting the Ongoing Phase 3 STOP-HAE Clinical Trial at the 2026 Annual EAACI Congress - ADARx Pharmaceuticals. https:\/\/www.adarx.com\/adarx-pharmaceuticals-to-present-onvuzosiran-adx-324-phase-1-2-clinical-data-supporting-the-ongoing-phase-3-stop-hae-clinical-trial-at-the-2026-annual-eaaci-congress\/ (last accessed June 29, 2026)"},{"key":"5754_CR36","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT06960213 (last accessed June 29, 2026)"},{"issue":"2","key":"5754_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2025.12.94838","volume":"157","author":"Y Zhi","year":"2026","unstructured":"Zhi\u00a0Y, Zhao\u00a0X, Zhu\u00a0R et\u00a0al (2026) Significant HAE Attack Reduction with BW-20805, a\u00a0Long-Acting Prophylactic Injection- An Ongoing Phase\u00a02\u00a0Study in Adult with Hereditary Angioedema. J\u00a0Allergy Clin Immunol 157(2):AB426. https:\/\/doi.org\/10.1016\/j.jaci.2025.12.94838","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"5754_CR38","unstructured":"Study Details | NCT06846398 | A Phase 2 in Adult Subjects With Hereditary Angioedema | https:\/\/clinicaltrials.gov\/study\/NCT06846398"},{"key":"5754_CR39","unstructured":"(2022) press release 16SEP2022. https:\/\/ir.intelliatx.com\/news-releases\/news-release-details\/intellia-therapeutics-announces-positive-interim-clinical-data. Zugegriffen: 16. Juni 2026"},{"issue":"5","key":"5754_CR40","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1056\/NEJMoa2309149","volume":"390","author":"HJ Longhurst","year":"2024","unstructured":"Longhurst\u00a0HJ, Lindsay\u00a0K, Petersen\u00a0RS, Fijen\u00a0LM, Gurugama\u00a0P, Maag\u00a0D, Butler\u00a0JS, Shah\u00a0MY, Golden\u00a0A, Xu\u00a0Y, Boiselle\u00a0C, Vogel\u00a0JD, Abdelhady\u00a0AM, Maitland\u00a0ML, McKee\u00a0MD, Seitzer\u00a0J, Han\u00a0BW, Soukamneuth\u00a0S, Leonard\u00a0J, Sepp-Lorenzino\u00a0L, Clark\u00a0ED, Lebwohl\u00a0D, Cohn\u00a0DM (2024) CRISPR-Cas9 In Vivo Gene Editing of KLKB1 for Hereditary Angioedema. N Engl J Med 390(5):432\u2013441. https:\/\/doi.org\/10.1056\/NEJMoa2309149","journal-title":"N Engl J Med"},{"issue":"5","key":"5754_CR41","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1056\/NEJMoa2405734","volume":"392","author":"DM Cohn","year":"2025","unstructured":"Cohn\u00a0DM, Gurugama\u00a0P, Magerl\u00a0M, Katelaris\u00a0CH, Launay\u00a0D, Bouillet\u00a0L, Petersen\u00a0RS, Lindsay\u00a0K, Ayg\u00f6ren-P\u00fcrs\u00fcn\u00a0E, Maag\u00a0D, Butler\u00a0JS, Shah\u00a0MY, Golden\u00a0A, Xu\u00a0Y, Abdelhady\u00a0AM, Lebwohl\u00a0D, Longhurst\u00a0HJ (2025) CRISPR-Based Therapy for Hereditary Angioedema. N Engl J Med 392(5):458\u2013467. https:\/\/doi.org\/10.1056\/NEJMoa2405734","journal-title":"N Engl J Med"},{"key":"5754_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1681763","volume":"16","author":"F Johnson","year":"2025","unstructured":"Johnson\u00a0F, Hofauer\u00a0B (2025) Unraveling angioedema: diagnostic challenges and emerging therapies. Front Immunol 16:1681763. https:\/\/doi.org\/10.3389\/fimmu.2025.1681763","journal-title":"Front Immunol"},{"key":"5754_CR43","doi-asserted-by":"publisher","first-page":"336","DOI":"10.5414\/ALX02532E","volume":"8","author":"M Fasshauer","year":"2024","unstructured":"Fasshauer\u00a0M, Wedi\u00a0B (2024) Hereditary angioedema (HAE) in children and adolescents: New treatment options. Allergol Select 8:336\u2013345. https:\/\/doi.org\/10.5414\/ALX02532E","journal-title":"Allergol Select"},{"key":"5754_CR44","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1111\/pai.13309","volume":"31","author":"V Wahn","year":"2020","unstructured":"Wahn\u00a0V, Aberer\u00a0W, Ayg\u00f6ren-P\u00fcrs\u00fcn\u00a0E, Bork\u00a0K, Eberl\u00a0W, Fa\u00dfhauer\u00a0M, Kr\u00fcger\u00a0R, Magerl\u00a0M, Martinez-Saguer\u00a0I, Sp\u00e4th\u00a0P, Staubach-Renz\u00a0P, Weber-Chrysochoou\u00a0C (2020) Hereditary angioedema in children and adolescents - A consensus update on therapeutic strategies for German-speaking countries.\u00a0Pediatr Allergy Immunol 31:974\u2013989. https:\/\/doi.org\/10.1111\/pai.13309","journal-title":"Pediatr Allergy Immunol"},{"key":"5754_CR45","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/j.jaip.2021.11.011","volume":"10","author":"Paula Busse","year":"2022","unstructured":"Busse P, Kaplan A (2022) Specific Targeting of Plasma Kallikrein for Treatment of Hereditary Angioedema: A Revolutionary Decade. J\u00a0Allergy Clin Immunol Pract 10:716\u2013722. https:\/\/doi.org\/10.1016\/j.jaip.2021.11.011","journal-title":"J Allergy Clin Immunol Pract"},{"key":"5754_CR46","unstructured":"ClinicalTrials.gov, NCT05819775. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05819775 [Last accessed June\u00a016, 2026]"}],"container-title":["Die Dermatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-026-05754-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00105-026-05754-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-026-05754-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T16:04:29Z","timestamp":1788451469000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00105-026-05754-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":46,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["5754"],"URL":"https:\/\/doi.org\/10.1007\/s00105-026-05754-7","relation":{},"ISSN":["2731-7005","2731-7013"],"issn-type":[{"value":"2731-7005","type":"print"},{"value":"2731-7013","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,4]]},"assertion":[{"value":"27 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.\u00a0Fasshauer: pers\u00f6nlich keine; IDCL: Teilnahme an NIS-Nr. 609 \u201eProphylaxis Impact on Quality of Life Impairment of HAE Patients with Lower Annual Base Attack Rates (PIQHAR)\u201c und NCT07251933 \u201eA\u00a0Multi-national Real-world Outcomes and Treatment Patterns Study of Lanadelumab (Takhzyro) in Paediatric Patients With Hereditary Angioedema (TAHORA)\u201c. N.\u00a0Dominas: Referenten- und Beratert\u00e4tigkeiten f\u00fcr CSL Behring, Takeda Pharmaceutical, Neopharmed Gentili, Otsuka Pharma, KalVista Pharmaceuticals.","order":1,"name":"Ethics","label":"Interessenkonflikt","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autorinnen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}}]}}